Clinical trial · Interventional
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement. Conducted at the Centre de Référence Liégeois des Maladies Neuromusculaires in Liège, Belgium, the study will enroll 300 ambulant patients, including individuals with neuromuscular disorders and obesity. Using the Syde® wearable device, the study aims to continuously monitor motor function in real-life settings over a period of up to two years. The primary objective is to evaluate the utility of digital mobility outcomes, such as the 95th centile of stride velocity (SV95C), as reliable and objective endpoints for future clinical trials.
Conditions
Conditions (12)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ataxia, Spinocerebellar | — | UNRESOLVED | — |
| Charcot Marie Tooth Disease (CMT) | — | UNRESOLVED | — |
| Facio-Scapulo-Humeral Dystrophy | — | UNRESOLVED | — |
| Glycogen Storage Disease Type II Pompe Disease | — | UNRESOLVED | — |
| Hereditary Spastic Paraplegia | — | UNRESOLVED | — |
| Huntington Disease | — | UNRESOLVED | — |
| Myasthenia Gravis | — | UNRESOLVED | — |
| Myasthenic Syndrome | — | UNRESOLVED | — |
| Myotonic Dystrophy 1 | — | UNRESOLVED |
Interventions
Interventions (16)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 9-Hole Peg Test (9-HPT) | Diagnostic Test | — | UNRESOLVED |
| Dynamometric measurements of muscle strength | Diagnostic Test | — | UNRESOLVED |
| Patient's Global Impression of Change (PGIC) | Other | — | UNRESOLVED |
| Quantitative Myasthenia Gravis (QMG) | Diagnostic Test | — | UNRESOLVED |
| Syde | Device | — | UNRESOLVED |
| Test of rising from the floor (TRF) | Diagnostic Test | — | UNRESOLVED |
| The 10-meter test (10MWT) | Diagnostic Test | — | UNRESOLVED |
| The 4 stair-climbing test (4SC) | Diagnostic Test | — |
Design
Arms and outcomes
Arms (8)
- type
- EXPERIMENTAL
- label
- Neuromuscular condition - Muscle disease
- interventionNames
- Device: Syde
- Diagnostic Test: The 6-minute walk test (6MWT)
- Diagnostic Test: The 10-meter test (10MWT)
- Diagnostic Test: The 4 stair-climbing test (4SC)
- Diagnostic Test: Test of rising from the floor (TRF)
- Other: Patient's Global Impression of Change (PGIC)
- type
- EXPERIMENTAL
- label
- Neuromuscular condition - Neuropathy
- interventionNames
- Device: Syde
- Diagnostic Test: Dynamometric measurements of muscle strength
- Diagnostic Test: The 6-minute walk test (6MWT)
- Diagnostic Test: The 10-meter test (10MWT)
- Diagnostic Test: The 4 stair-climbing test (4SC)
- Diagnostic Test: Test of rising from the floor (TRF)
- Diagnostic Test: The Charcot-Marie-Tooth examination score (CMTES)
- Diagnostic Test: 9-Hole Peg Test (9-HPT)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Ambulant patients (i.e. able to walk 10 meters without assistance) * Confirmed diagnosis by the investigator based on current gold standard in his/her disease (genetic testing, clinical criteria, etc.) * Myotonic dystrophy type 1 (DM1) and Charcot-Marie-Tooth (CMT) patients should present sensitive of motor signs on physical examination. * Myasthenic patients should be seropositive, and Myasthenia Gravis Foundation of America (MGFA) class II to IV. * Patient with morbid obesity (Body Mass Index\> or = 35 at inclusion visit). * Signed informed consent form by patient him/herself and patient willing and able to comply with all study procedures. Exclusion Criteria: * Non-ambulant patients * Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed * Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs * A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion * Patients who are participating in an interventional clinical trial * Pregnant or breastfeeding women
References
Publications (0)
Data not yet available